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Lung cancer was the most common cause of cancer death in 1996
in the United States and Germany (Parker, 1996). The World
Health Organization histologic classification of lung cancer
(World Health Organization, 1982) describes 3 major subtypes of
non-small cell lung cancer (NSCLC), squamous cell carcinoma
(SCC), adenocarcinoma (AC) and large cell carcinoma (LC)
which represent approximately 75% of all lung cancer cases.
Radical surgery (RO resection) offers the only chance for cure in
patients with NSCLC and survival probabilities are mainly
dependent on tumour stage (Mountain, 1986; Buelzebruck et al,
1992).
A variety of molecular markers have been implicated both in the
pathogenesis and prognosis of NSCLC (Gazdar, 1992; Minna,
1993; Johnson, 1995). Conflicting results, however, were reported
in the literature and this might be due to small sample sizes, non-
homogeneous populations (Simon and Altman, 1994) and the use
of optimal cut-off values (Altman et al, 1994). Also, various tech-
niques were employed without proper methodological evaluation
(Press et al, 1994). In general, data on treatment quality control are
lacking in molecular prognostic marker studies although they are
essential for the interpretation of trial results (Holmes, 1994).
We first reported differential expression of the c-erbB-2 gene in
small cell versus non-small cell lung cancer (Schneider et al, 1989)
and shortly thereafter c-erbB-2 protein (p185) overexpression was
reported to predict shortened survival in lung adenocarcinomas in
a retrospective analysis (Kern et al, 1990). We therefore started a
prospectice study in patients with curatively (RO category)
resected NSCLC to conclusively evaluate the prognostic impor-
tance of increased expression of c-erbB-2 protein. In addition, the
prognostic impact of mutations in the p53 tumor-suppressor gene
(Chiba et al, 1990; Kishimoto et al, 1992; Mitsudomi et al, 1993;
Carbone et al, 1994; Ryberg et al, 1994; Sauter et al, 1995) and c-
Ki-ras gene (Rodenhuis and Slebos, 1992; Keohavong et al, 1996;
Rosell et al, 1996) were evaluated since contradictory results were
reported in the literature. The major purpose of this study was to
evaluate if multiple molecular marker (c-Ki-ras, p53 and c-erbB-2)
testing results in a better definition of low and high risk NSCLC
patients for failure of standardized treatment.
PATIENTS AND METHODS
Study design, demographic data and follow-up
From 136 patients consecutively operated for the clinical diag-
nosis of lung cancer, 103 patients fulfilled the following inclusion
criteria and were prospectively evaluated: (I) NSCLC histology of
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SummaryA prospective study was performed in patients with non-small cell lung cancer (NSCLC) to evaluate the prognostic importance of
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regression model including a multiple molecular marker parameter (negative for all 3 markers versus positive for at least one marker),
histopathological stage (P < 0.00001), respectively the pT (P < 0.01) and pN (P < 0.00001) categories and the multiple molecular marker
parameter (P < 0.01) were of significant prognostic importance. This study demonstrates that testing 3 molecular markers (c-Ki-ras, p53 and
c-erbB-2) improves estimation of prognosis compared to single marker testing and appears to define low (82.6% ±7.9% 5-year survival) and
high risk (40.2% ±5.5% 5-year survival) groups for treatment failure in potentially curative (RO) resected NSCLC. ©2000 Cancer Research
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squamous cell carcinoma (SCC), adenocarcinoma (AC) or large
cell carcinoma (LC); (II) complete tumour resection (RO category;
Hermanek et al, 1993) by at least a lobectomy as minimal extent of
resection; (III) systematic lymphadenectomy as quality control
(Buelzebruck et al, 1992; Holmes, 1994); (IV): histopathological
UICC stage I, II or IIIA; (V): postoperative radiotherapy for
histopathological stage IIIA; (VI) no prior history of a malignant
tumour or radiation and/or chemotherapy before sampling of the
tissue specimes to be analysed; (VII) no perioperative 30-days
lethality.
A total of 103 patients were included in the analysis. There were
79 male and 24 female patients with a median age of 63.5 years
(min 34.5 y; max. 82.5 y). Tumours were radically removed by
lobectomy (n = 67; 65%), bilobectomy (n = 13; 12.6%); pneu-
monectomy (n = 11; 10.7%) and extended pneumonectomy (n =
12; 11.7%) including mediastinal lymphadenectomy. Distribution
of histopathological stages according to the UICC TNM
Classification (I–IIIA), histological types according to the WHO
classification (SCC, AC, LC) and histopathological grading of the
primary tumour (G1–G3) is indicated (n) in Table 1. All patients in
UICC Stage IIIA received postoperative radiotherapy.
Median follow-up was 86.8 months (min. 63.3; max. 105.2
months) and no patients was lost to follow-up. Patients were seen
at 3 month intervals during the first postoperative year, every 6
months in the second and third year and once a year thereafter.
Evaluation consisted of physical examination, biochemical profile,
chest radiograph, CT scan of brain, chest and abdomen, abdominal
ultrasound and technetium bone scan. Data on recurrences and
cause of death were obtained for all patients.
Tissue aquisition
Tissue for DNA analysis was obtained immediately after lung
resection before starting mediastinal lymphadenectomy and was
frozen in liquid nitrogen. Tissue was analysed from the following
2 locations: tumour and uninvolved lung tissue taken from the
greatest distance to the tumour. Tumour tissue was selected from
areas with at least 75% malignant cells.
DNA analysis (c-Ki-ras and p53 gene)
DNA preparation was carried out with a DNA extraction kit
according to the recommendations of the manufacturer (Stratagene
Inc, LaJolla, CA). For PCR amplification, oligonucleotide primer
pairs (MWG Biotech, Ebersberg, Germany) for exons 5–9 were
chosen as reported (Imamura et al, 1993). The primers used for 
c-Ki-ras were: exon1: PKE1–1 (sense): 5¢-ATGACTGAATA-
TAAACTTGT-3¢; PKE1–2 (antisense): 5¢-CTCTATTGTTGGAT-
CATATT-3¢; exon2: PKE2–1 (sense): 5¢-TTCCTACAGGAA-
GCAAGTAGTA-3¢; PKE2–2 (antisense): 5¢-ACACAAAGAA-
AGCCCTCCCCA-3¢. The PCR, SSCP and DNA sequencing
conditions were identical for p53 and c-Ki-ras gene analysis and
have been previously reported with a sensitivity to detect 1
mutated cell in 10 non-mutated cells (Schneider et al, 1996).
Immunohistochemistry (c-erbB-2 gene expression)
p185 immunostaining was performed on 6 mm cryostat sections.
Frozen sections were air dried and fixed in acetone for 30 min
followed by chloroform for 30 min both at 20°C. Sections were
incubated for 30 min with a monoclonal IgG1 c-erbB-2 antibody
(anti-c-erbB-2, Triton Biosciences, Alameda, CA, USA) diluted
1:500 that recognizes an epitope of the extracellular region of
p185 and specifically immunoprecipitates p185 in Western blot-
ting experiments (Iglehart et al, 1990). Staining was performed
with the alkaline-phosphatase-antialkaline-phosphatase (APAAP)-
complex (Dakopatts, Glostrup, Denmark) method as reported
(Boenisch, 1989). Control sections for all probes were stained both
after incubation with an isotype-specific monoclonal mouse anti-
body MOPC 21 (Sigma, St. Louis, MO, USA) and by omitting the
primary antibody. Three frozen sections with paired tumour and
normal lung tissue were processed for each patient probe. Scoring
of immunohistochemical results was performed by two indepen-
dent pathologists (JB and JM) who were blinded with regard to
clinical data. The immunohistochemical staining was scored nega-
tive (grade 0) if membrane staining was absent, unequivocally
positive but weak membrane staining (grade 1), moderate
membrane staining (grade 2) and strong membrane staining (grade
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Table 1 Survival in NSCLC based on clinical parameters
Parameter n 5-year survival (%) Median survival CI 95% P value
± SD (months)
UICC stage I 49 73.1 ± 6.3 n.r. –
II 23 55.7 ± 10.4 n.r. – <0.0001
III A 31 7.5 ± 5.3 18.8 ± 2.3 14.2; 23.3
pT pT1 24 70.8 ± 9.2 n.r. –
pT2 65 48.6 ± 6.2 59.7 – <0.009
pT3 14 21.4 ± 10.9 26.4 ± 7.3 12.0; 40.8
pN pN0 55 70.6 ± 6.1 n.r. –
pN1 29 43.4 ± 9.4 45.4 ± 11.6 22.6; 68.2 < 0.00001
pN2 19 0 16.7 ± 2.9 10.9; 22.4
Histology SCC 49 54.5 ± 7.1 n.r. –
AC 37 40.3 ± 8.0 45.4 ± 9.4 26.9; 63.9 n.s.
LC 17 58.8 ± 11.9 n.r. –
Grading G1 1( n = 1)* – –
G2 23 51.8 ± 10.4 n.r. – n.s.
G3 79 50.2 ± 5.6 63.9 –
Abbreviations: n.r. (not reached); – (cannot be calculated); CI 95% (95% confidence interval); n.s. (not significant);
n (number of patients)3). There was no inter-observer variation in grade 0 and grade 3
staining, however, there was significant (P < 0.01) inter-observer
variation in grade 1 and grade 2 staining by Kendall’s test
(Spurrier and Hewett, 1980). Therefore, the 2 groups (grade 1 and
2) were combined to the group of unequivocally positive
low–moderate p185 expression.
Statistical analysis
Kendall’s analysis of concordance (Spurrier and Hewett 1980) was
applied to test for inter-observer variation in evaluation of p185
immunohistochemical staining. Association of gene mutations or
gene expression with clinico-pathological parameters were evalu-
ated using the Chi-Square-Test. Correlations between groups were
assessed by Spearman’s correlation coefficient test. Survival was
estimated according to Kaplan and Meier (1958). Univariate
analysis was performed with the log-rank test (Mantel, 1966) and
multivariate analysis with the Cox Proportional Hazard
Regression Model (Cox, 1972) and significance was determined
by c2 analysis. The level of significance was set to P < 0.05.
RESULTS
Clinical data
Median and 5-year survival rates depending on various clinical
variables are summarized in Table 1. Histopathological UICC
tumour stage (P < 0.0001), pT category (P < 0.009), pN category
(P < 0.00001) were of significant prognostic importance using the
log rank test. Gender, age and grading of the primary tumour had
no prognostic impact on survival.
C-erbB-2 protein analysis
No expression of p185 was detected in 9/103 (8.7%), low-
moderate expression in 38/103 (36.9%) and overexpression in
56/103 (54.4%) NSCLC samples (Figure 1). p185 overexpression
was not limited but significantly (P < 0.01) associated with AC
histology (31/56) compared to SCC (19/56) and LC (6/56). p185
overexpression was not associated with UICC histopathological
tumour stage or grading of the primary tumour. NSCLC with p185
overexpression had a significantly reduced median and 5-y
survival probability (P < 0.05) as shown in Table 2. Subgroup
analysis based on the histological subtype revealed that p185 over-
expression was significantly (P < 0.01) associated with reduced
median and 5-year survival rates for patients with AC histology 
(P < 0.01) as shown in Table 2.
c-Ki-ras analysis
SSCP analysis and DNA sequencing revealed the presence of c-
Ki-ras mutations in 17/103 (16.5%) NSCLC. Mutations were
significantly associated with AC histology (P < 0.005) and were
present in 12/37 (32.4%) AC compared to 3/49 (6.1%) SCC and
2/15 (11.8%) LC. Detection of c-Ki-ras mutations were not associ-
ated with UICC histopathological tumour stage or grading of the
primary tumour. 15/17 point mutations were found in codon 12,
2/17 in codon 13 and no mutation in codon 61. The predominant
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Figure 1 Representative example of c-erbB-2 immunohistochemistry from a
poorly differentiated adenocarcinoma (magnification 400´) showing
overexpression of p185 with intensive red membrane staining (arrow) within
the tumour (t). The interspersed stroma (s) is completely negative
Table 2 Survival in NSCLC based on molecular parameters
Molecular n Subtype 5-year survival (%) Median survival CI 95% P
parameter ± SD (months) ± SD value
p185 GRD 0 9 ALL 77.7 ± 13.8 n.r. –
GRD 1/2 38 54.6 ± 8.1 n.r. –
GRD 3 56 38.3 ± 7.2 39.3 ± 8.9 21.7; 56.9 <0.05
GRD 0 0 AC Ø Ø Ø
GRD 1/2 6 81.8 ± 16.4 n.r. –
GRD 3 31 32.2 ± 8.4 35.8 ± 9.8 16.6; 55.0 <0.01
Ki-ras NEG 86 ALL 50.6 ± 5.4 63.9 –
POS 17 47.0 ± 12.1 46.7 – n.s.
NEG 25 AC 38.7 ± 9.8 44.0 ± 19.7 5.9; 82.7
POS 12 41.6 ± 14.2 45.4 ± 6.4 32.9; 58.0 n.s.
p53 NEG 57 ALL 53.6 ± 6.6 n.r. –
POS 46 45.4 ± 7.3 43.1 ± 16.5 10.8; 75.5 n.s.
NEG 20 SCC 64.8 ± 10.7 n.r. –
POS 29 48.0 ± 9.3 51.7 – n.s.
Abbreviations: GRD (grading of immunohistochemical staining of p185: 0: no expression, 1/2: low-moderate expression, 2:
overexpression); NEG (negative for c-Ki-ras or p53 mutations); POS (positive for c-Ki-ras or p53 mutations); n.r. (not reached); 
– (cannot be calculated); n.s. (not significant); CI 95% (95% confidence interval); Ø: no cases; n (number of patients)type of mutation was a G ® T transversion in position 1 of codon
12 (glycine ® cysteine; 8/17, 47%), with a G ® T transversion in
position 2 of codon 12 occurring in 11.8% of cases (glycine ®
valine; 2/17), a G ® C transversion in position 2 in 11.8% (glycine
® alanine; 2/17), a G ® A transition in position 2 of codon 12 in
17.6% (glycine ® aspartic acid; 3/17) and a G ® T transversion in
position 1 of codon 13 (glycine ® cysteine; 2/17) in 11.8% of the
cases.
Presence of c-Ki-ras mutations were not associated with
reduced median and 5-year survival rates and subgroup analysis
was statistically only possible for AC histology and did not show
any significant impact on survival (Table 2).
p53 analysis
DNA analysis of the p53 gene demonstrated the presence of muta-
tions in 46/103 (44.7%) NSCLC and representative examples are
shown in Figure 2. p53 mutations were significantly (P < 0.01)
associated with the histological NSCLC subtype and were more
frequent in SCC (59.2%) than AC (32.4%) or LC (29.4%). There
was no association of p53 mutations with UICC stage and grading
of the tumour. The distribution of the exon location and types of
mutation are summarized in Table 3. Survival rates did not differ
between NSCLC with and without p53 mutations (Table 2) and
subgroup analysis demonstrated a tendency towards a reduced
survival probability in SCC which was not statistically significant
(Table 2).
Multiple molecular parameter (c-Ki-ras, p53 and 
c-erbB-2) analysis
24/103 (23.3%) NSCLC did not show any alteration in one of the
3 markers (c-Ki-ras, p53 and p185) and are therefore multiple
parameter marker negative. One parameter positivity was
observed in 25/103 (24.3%) for p185, 20/103 (19.4%) for p53 and
in 0/103 NSCLC for c-Ki-ras. In this analysis, the 2 subgroups
with no expression of p185 and low-moderate p185 expression
were combined to one group (no p185 overexpression) since there
were no differences in survival probabilities by log rank test (P =
0.5). Two molecular markers were positive in 8/103 (7.8%) for
p185 and c-Ki-ras, 17/103 (16.5%) for p185 and p53 and 3/103
(2.9%) NSCLC for c-Ki-ras and p53 gene mutations. 6/103 (5.8%)
showed abnormalities in all 3 parameters. There was no significant
association of multiple marker positivity with UICC stage.
Survival data based on different combinations of the markers
tested are shown in Table 4. Log-rank testing was statistically
significant (P < 0.001) and demonstrated that tumours with single,
double and triple marker positivity had a significantly worse prog-
nosis when compared to 3 parameter negative tumours. Statistical
subgroup analysis for the 8 combinations was not possible since 4
combinations (Ki-ras only, Ki-ras and p185, Ki-ras and p53, 3
marker positive) were infrequently detected (Table 4).
For further statistical analysis NSCLC were stratified as
multiple parameter negative (no alteration in any of the 3 markers)
or positive if one or more markers showed an alteration. Survival
curves are shown in Figure 3 and demonstrate a significant differ-
ence (P < 0.001) with 5-year survival probabilities of 82.6% 
(± 7.9%) for negative cases compared to 40.2% (±5.5%) for
positive cases.
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Figure 2 Direct DNA sequencing analysis of 2 representative tumours and
corresponding normal lung tissues. One tumour (top) shows an A ® G
transition-type missense mutation (arrows) in exon 5 and the other (bottom) a
G ® T transversion-type (arrows) missense mutation in exon 8
Table 3 Location and type of p53 mutation in NSCLC
Location Transversion Transition Deletion Insertion Total
Exon 5 15 9 1 1 26
(56.52%)
Exon 6 1 0 1 0 2
(4.35%)
Exon 7 7 1 2 0 10
(21.74%)
Exon 8 2 3 3 0 8
(17.39%)
Total 25 13 7 1 46
(54.35%) (28.26%) (15.22%) (2.17%) (100%)
Table 3 shows the distribution of exon locations and types of p53 mutations in 46 mutation-positive NSCLC.
Mutations were most frequently located on exon 5 (56.52%) and were predominantly transversion-type
mutations (54.35%). All mutations led to amino acid changesMultivariate analysis
Four logistic regression models were tested. Model A included
parameters gender, age, histological type, UICC tumour stage,
grading of the primary tumour, p185 expression, p53 mutation and
c-Ki-ras mutation and model B the pT and pN categories instead 
of histopathological tumour stage. Only UICC tumour stage 
(P < 0.00001) in model A respectively the pT (P < 0.01) and pN 
(P < 0.00001) categories in model B were of independent prog-
nostic importance. In models C and D we used the multiple mole-
cular parameter instead of p185, c-Ki-ras and p53. UICC tumour
stage (P < 0.00001) in model C, the pT (P < 0.01) and pN (P <
0.00001) categories in model D and the multiple molecular para-
meter (P > 0.01) in models C and D were of significant indepen-
dent prognostic importance. Table 5 shows the statistically
significant parameters in the 4 regression models.
DISCUSSION
We designed this prospective study to test the hypothesis that p185
overexpression, c-Ki-ras mutations and p53 mutations by them-
selves or in combination are of prognostic importance in patients
with curatively (UICC RO) resected NSCLC. Our treatment
results for curatively (UICC RO) resected NSCLC based on
various parameters (UICC tumour stage, pT-category, pN-cate-
gory, grading of the primary tumour and histological subtype) as
shown in Table 1 are in good agreement with the large reference
series in the literature (Buelzebruck et al, 1992; Mountain, 1986;
Naruke et al, 1988).
The major problem in comparing studies of p185 expression in
NSCLC is the enormous variation in frequencies of NSCLC
tumours scored positive for p185. Overerexpression of p185 were
reported in 28–80% AC (Kern et al, 1990; Bongiorno et al, 1994;
Tateishi et al, 1991; Shi et al, 1992; Pfeiffer et al, 1996), 2–45%
SCC (Kern et al, 1990; Pfeiffer et al, 1996; Shi et al, 1992;
Tateishi, 1992; Volm et al, 1992) and 0–20% LC (Kern et al, 1990;
Pfeiffer et al, 1996). Some of these studies used paraffin embedded
slides (Kern et al, 1990; Tateishi, 1992; Volm et al, 1992) or
applied p185 antiserum (Kern et al, 1990; Tateishi et al, 1991;
Pfeiffer et al, 1996) for immunohistochemistry.
Chiu et al (1994) could convincingly demonstrate in a
controlled comparative analysis of paraffin-embedded slides and
cryostat sections that rates of p185 overexpression were approxi-
mately doubled in cryostat sections. Press et al (1994) tested 
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Table 4 Survival based on multiple molecular marker combinations
Molecular parameter No. cases 5-year survival (%) Median survival CI 95%
± SD (months) ± SD
3 marker negative 24 82.6 ± 7.9 n.r. –
p185 only 25 27.6 ± 9.2 20.8 ± 6.0 9.0–32.7
p53 only 20 28.2 ± 10.1 31.6 ± 16.7 0.0–64.5
Ki-ras only 0 – – –
Ki-ras and p185 8 37.5 ± 17.1 35.8 ± 11.0 14.1–57.5
Ki-ras and p53 3 66.6 ± 27.2 n.r. –
p185 and p53 17 56.2 ± 12.4 n.r. –
3 marker positive 6 50.0 ± 20.4 45.4 –
Abbreviations: n.r. (not reached) – (cannot be calculated); CI 95% (95% confidence interval)
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Figure 3 Kaplan-Meier curves based on the multiple molecular marker
parameter. NSCLC negative for the 3 markers c-Ki-ras, p53 and p185
(multiple marker negative) are compared to tumours positive for at least one
of the 3 tested markers (multiple marker positive)
Table 5 Cox-proportional hazard regression models
Model Parameter P value Odds ratio CI 95%
A Stage 0.00001
I/II 0.03 2.68 1.08–6.61
I/IIIA 0.00001 9.17 4.36–19.26
B pT 0.01
pT1/pT2 0.02 2.22 0.94–5.22
pT1/pT3 0.003 4.31 1.51–12.27
pN 0.00001
pN0/pN1 0.03 1.91 1.08–5.14
pN0/pN2 0.00001 8.59 4.25–17.39
C Stage 0.00001
I/II 0.07 2.18 0.92–5.17
I/IIIA 0.00001 6.19 3.07–12.49
Triple marker 0.01 3.55 1.25–10.09
D pT 0.01
pT1/pT2 0.03 2.38 1.05–5.41
pT1/pT3 0.004 4.22 1.56–11.39
pN 0.00001
pN0/pN1 0.05 2.05 0.99–4.24
pN0/pN2 0.00001 7.71 3.80–15.62
Triple marker 0.01 3.76 1.34–10.59
Abbreviations: CI 95%: 95% confidence interval for odds ratio. Parameter
section: e.g. stage I/II means stage I compared to stage II7 polyclonal and 21 monoclonal anti-c-erbB-2 antibodies and
demonstrated variations in positive membrane staining between
2–30% as well as significant differences in sensitivity and
specificity. As a consequence, different results were reported
concerning the impact of c-erbB-2 protein overexpression on
survival in NSCLC. Kern et al (1990) and Tateishi et al (1991)
reported significantly reduced survival rates for AC over-
expressing p185. Both studies are retrospective analyses using
paraffin-embedded slides and polyclonal antiserum. Careful
review of the data presented by Kern et al (1990) reveals that their
stage IIIA patients had a better prognosis than the patients in stage
II and that the pN-category was not of significant prognostic
importance (P = 0.95). Pfeiffer et al (1996) did not report differ-
ences in survival in AC overexpressing p185 however, the staining
frequency in AC was only 26%. In our study, p185 overexpression
is of significant prognostic importance for AC histology (P < 0.01)
by univariate analysis but not of independent prognostic impor-
tance by multivariate analysis. 
Presence of c-Ki-ras mutations were reported in 15.7–36%
(Kern, 1994; Keohavong et al, 1996; Mitsudomi et al, 1991;
Rosell et al, 1996; Slebos et al, 1990; Sugio et al, 1992) of AC
NSCLC which is consistent with our result of 32%. Slebos et al
(1990) and Mitsudomi et al (1991) reported significant differ-
ences in survival if c-Ki-ras mutations were present in AC
NSCLC. Kern and colleagues (1994) could not demonstrate
significant impact on survival in 16/44 AC lung cancer patients
with c-Ki-ras mutations however demonstrated an independent
negative prognostic effect by multivariate analysis if c-Ki-ras
mutations and p185 overexpression was present in AC (P <
0.004). In our study c- Ki-ras gene mutations were not of prog-
nostic significance by univariate and multivariate analysis for
patients with curatively resected AC NSCLC which is consistent
with the more recently published reports (Keohavong et al, 1996;
Rosell et al, 1996).
Mutations in the p53 tumour-suppressor gene were reported in
32%–52% NSCLC (Chiba et al, 1990; Horio et al, 1993;
Kishimoto et al, 1992; Mitsudomi et al, 1993; Carbone et al,
1994; Ryberg et al, 1994; Sauter et al, 1995) and reported results
are within the range of the 45% detected in our series. We did not
find a significant prognostic impact on survival for all NSCLC if
p53 mutations were present by both univariate or multivariate
analysis. Horio et al (1993) reported significant worse survival
data for 35/70 (49%) p53 mutation-positive NSCLC with poten-
tially curative resections (P < 0.014) including subgroup analysis
for stages I and II tumours (P < 0.016) and an independent impact
on survival by multivariate analysis (P < 0.013). Mitsudomi and
colleagues (1993) also showed a significant negative prognostic
impact of p53 mutations (P < 0.01) but subgroup analysis
revealed significant prognostic differences for advanced UICC
stages IIIA to IV (P < 0.009) and not for early stages I and II (P =
0.28). On the contrary, Top et al (1995) who evaluated 54 patients
with resected NSCLC did see a better prognosis in p53 mutation-
positive tumours. The lung cancer study group 871 (Carbone et
al, 1994) failed to show a prognostic impact in curatively resected
NSCLC carrying p53 mutations (P = 0.62) but detected a weak
negative survival correlation with positive p53 immunostaining
(P < 0.05).
One of the critical questions is the evaluation of the interrela-
tionships between factors reported to be of prognostic importance.
Only few studies have already addressed this question and Kern
and colleagues (1994) examined the interrelationship of c-Ki-ras
mutations and p185 overexpression and found a significantly
worse prognosis for lung adenocarcinomas harbouring c-Ki-ras
mutations and p185 overexpression. Volm et al (1992) examined
the expression at the protein level of c-erbB-1, c-erbB-2, c-fos, c-
myc and p53 using immunohistochemistry and found that c-erbB-
1 and c-fos expression may serve as prognostic factors for the
aggressiveness of SCC and response to chemotherapy.
Our study is the first prospective controlled study examining the
three most frequently examined and controversially discussed
prognostic parameters in RO resected NSCLC: p53 mutations, 
c-Ki-ras mutations and c-erbB-2 protein expression. Our data
convincingly demonstrate that 3 parameter negative tumours have
a highly significant better prognosis than tumours testing positive
for at least one molecular marker.
The major conclusion of this study is that multiple molecular
marker testing is necessary to detect an independent prognostic
impact on survival and is therefore superior to single marker
testing if p53 and c-Ki-ras mutations and c-erbB-2 overexpression
are evaluated. Based on multiple molecular marker testing 2
groups of curatively resected NSCLC could be defined: a low-risk
group (multiple molecular marker negative) and a high-risk group
(multiple molecular marker positive) for failure of standardized
treatment.
This information might be most valuable in the planning of pre-
or postresection treatment strategies in future studies.
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